1. Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses.
- Author
-
Maarifi, Ghizlane, Martin, Marie-France, Zebboudj, Abderezak, Boulay, Aude, Nouaux, Pierre, Fernandez, Juliette, Lagisquet, Justine, Garcin, Dominique, Gaudin, Raphael, Arhel, Nathalie J., and Nisole, Sébastien
- Subjects
- *
CORONAVIRUSES , *COVID-19 , *SARS-CoV-2 , *INTERFERON regulatory factors , *ANTIVIRAL agents - Abstract
The increasingly frequent outbreaks of pathogenic viruses have underlined the urgent need to improve our arsenal of antivirals that can be deployed for future pandemics. Innate immunity is a powerful first line of defense against pathogens, and compounds that boost the innate response have high potential to act as broad-spectrum antivirals. Here, we harnessed localization-dependent protein-complementation assays (called Alpha Centauri) to measure the nuclear translocation of interferon regulatory factors (IRFs), thus providing a readout of innate immune activation following viral infection that is applicable to high-throughput screening of immunomodulatory molecules. As proof of concept, we screened a library of kinase inhibitors on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and identified Gilteritinib as a powerful enhancer of innate responses to viral infection. This immunostimulatory activity of Gilteritinib was found to be dependent on the AXL-IRF7 axis and results in a broad and potent antiviral activity against unrelated RNA viruses. [Display omitted] • Compounds that boost the innate response can act as broad-spectrum antivirals • Bioluminescence complementation is applied to measure nuclear translocation of IRFs • Screening for enhancers of immune signaling by SARS-CoV-2 identified Gilteritinib • Gilteritinib has broad antiviral activity that is dependent on the AXL-IRF7 axis Compounds that enhance innate immunity can constitute potent broad-acting antivirals. Maarifi et al. identify immunostimulatory molecules applying bioluminescence complementation to measure innate immune activation. By assessing kinase inhibitors on SARS-CoV-2-infected cells, they identify Gilteritinib as an enhancer of innate responses with broad-acting antiviral activity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF